Interview, Fireside Chat
Dr. Arie Belldegrun, Co-Founder and Executive Chairman, Allogene Therapeutics
- The human genome project was anticipated to be in full gear around 1996, with an expectation that building immune systems using tools available at the time was an early and primitive approach.
- A plan was established in 2009 to raise a $50 million fund for acquiring university technologies, a process where signing a Cooperative Research and Development Agreement (CRADA) was expected to take approximately one and a half years.
- A physician scientist is predicted to advance more effectively within university hierarchies compared to other profiles.
- Approximately 300 companies are currently estimated to be active in engineered T-cells, a figure that represents significant growth from the one or two companies present at the sector's inception.
- Agensis is expected to release a revolutionary drug for bladder cancer within the next few months.
- Amgen's David is anticipated to join the company as head of R&D if an opening exists following the observation of transformative patient results.
- Cougar is identified as holding a drug for prostate cancer, while Kite is noted to have a drug for lymphoma.